ACRV logo

ACRV
ACRIVON THERAPEUTICS INC

1,156
Mkt Cap
$60.44M
Volume
415,715.00
52W High
$3.56
52W Low
$1.05
PE Ratio
-0.77
ACRV Fundamentals
Price
$1.56
Prev Close
$1.55
Open
$1.53
50D MA
$1.59
Beta
1.73
Avg. Volume
738,397.87
EPS (Annual)
-$2.02
P/B
0.44
Rev/Employee
$0.00
$23.07
Loading...
Loading...
News
all
press releases
Research Analysts Set Expectations for ACRV Q1 Earnings
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...
MarketBeat·22d ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus...
MarketBeat·23d ago
News Placeholder
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday
Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-acrivon-therapeutics-inc-stock...
MarketBeat·24d ago
News Placeholder
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·1mo ago
News Placeholder
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer...
MarketBeat·1mo ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,024,627...
MarketBeat·2mo ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,521,144 shares, a...
MarketBeat·2mo ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
Adam Levy Acquires 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction on Wednesday, January 14th. The shares were acquired at an average...
MarketBeat·3mo ago
<
1
2
...
>

Latest ACRV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.